GILD News and Press, Gilead Sciences Inc. From 03/28/24

– Efficacy and Safety Profile of Once-Daily Vemlidy Demonstrated in Children Six Years of Age (Weighing at Least 25kg) and Older – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new ...

2024-03-28 08:23:29 ET Gilead Sciences ( NASDAQ: GILD ) has signed an exclusive license deal to develop and commercialize Xilio Therapeutics’ ( NASDAQ: XLO ) XTX301, an investigational tumor-activated IL-12 program with potential to treat a broad range of cancers....

— Gilead Granted Exclusive License to Xilio’s Tumor-Activated IL-12 Program, Including XTX301, a Clinical-Stage IL-12 Molecule with Potential to Treat a Broad Range of Cancers — Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today an...

2024-03-27 02:09:28 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

NORTHAMPTON, MA / ACCESSWIRE / March 26, 2024 / Dr. Thomas Odeny grew up in rural Kenya during the height of the HIV epidemic in sub-Saharan Africa. After graduating from medical school at the University of Nairobi, he decided to begin his career in HIV care as a way to give back to his communit...

2024-03-24 08:37:16 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The D...

2024-03-22 17:37:29 ET More on Gilead Sciences Gilead Sciences Finally Starts Succeeding Gilead Sciences: Realizing Financial Projections Is Key Gilead Sciences, Inc. (GILD) Barclays 26th Annual Global Healthcare Conference (Transcript) Dividend Roundup: Qual...

Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...

2024-03-21 04:43:11 ET Summary Gilead Sciences has a strong track record in curing Hepatitis C and a successful HIV business. The company has struggled with acquisitions but is expected to generate strong shareholder returns. Gilead Sciences has new businesses and milestones p...

2024-03-20 13:10:49 ET Summary Gilead Sciences has seen weak price momentum over the past year following the sales drop in its COVID-19 medication Veklury, even as sales-ex Veklury look alright and earnings have grown. The company has a relatively positive revenue and earnings gui...